Researchers at National Jewish Health and collaborating institutions have uncovered a critical mechanism driving persistent pulmonary fibrosis and identified a promising strategy to reverse it. The ...
SAN DIEGO - A novel, fixed-duration drug combination — consisting of a second-generation BTK inhibitor, called acalabrutinib, plus a BCL-2 inhibitor (venetoclax), with or without a third blood cancer ...
Scientists are developing therapies to eliminate chemotherapy-induced senescent 'zombie' cells, which may fuel inflammation and cancer relapse. These approaches include repurposing existing cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results